LGC Axolabs specialises in a new class of treatments whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics.

We use our many years of expertise to help our clients make them a success. Some of these treatments have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New treatments from this class are added every year.

Our broad range of services for therapeutic oligonucleotides and mRNAs includes bioinformatics, chemical synthesis of oligonucleotides, oligonucleotide conjugates and formulations, analytics, bioanalytics and in vitro testing.

LGC Axolabs expert team has 20+ years of experience in the development of oligonucleotide therapeutics and has access to excellent infrastructure.

We employ over 300 people and operate from three locations: Kulmbach and Berlin, Germany, and Petaluma, US.

We are well known, from big-pharma and biotech to academia and venture capital, for our profound knowledge, high quality standards and excellent research.

We count the majority of research groups in this field worldwide among our clients, including >20 big pharma enterprises, >250 biotech companies, >30 academic research institutes and venture capital firms.